INSIGHTS ON QUALITY CONTROL

• High Potency Fill Line

  Whether it's a liquid or lyophilized product, we provide capacity, quality, and expertise to ensure a stable supply of your promising therapeutics.

• The Hidden Costs Of GMP Qualification And How Your Supplier Can Help

  What should you be aware of before starting instrument qualification, and what can an instrument provider do to help you avoid the hidden costs of GMP qualification?

• Phase 1 Manufacturing: How To Prepare

  Explore the lead-up to Phase 1 clinical manufacturing and how drugs are manufactured for clinical research under cGMP.

• Future Of Robotics & Automation In Quality Control In Microbial Testing

  We discuss how automation based on the use of robotics and digital tools will transform the QC process in microbial testing labs to meet the productivity, data integrity and reliability requirements of Pharma 4.0.

• Our Biotech Success - Corvus

  4/13/2022

  Corvus, a small biotech developing precision medicines, primarily for oncology patients, was seeking to develop a monoclonal antibody called CPI06, now known as Mupadolimab.

• Complex Pump-Driven Blending In A Bioprocess Application

  7/8/2021

  There are quite a few applications that require multiple streams to converge into a single process flow. Two such examples are buffer formulation and liquid chromatography gradient elution. 

• Studying Analyte Binding To Syringe Filters During Filter Validation

  5/2/2022

  Filter validation is a critical part of various pharmaceutical QC tests and require accurate analyte quantitation, therefore analyte binding is an important factor.

• Leveraging Integration At Each Phase Of A Drug Delivery System Project

  4/8/2021

  By forging deeper partnerships with customers, the full depth and breadth of our knowledge, experience and competencies can bring benefits at multiple levels. See how an integrated offering helps at each phase of a drug delivery system project.

• Formulation Development From Preclinical To First-In-Human

  1/24/2022

  A compound with poor biopharmaceutical properties or improper formulation design could lead to a delay in the project or even program termination.